 |
|
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
Sehhoon Park, Ji-Yeon Kim, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
Korean J Intern Med. 2017;32(3):514-522. Published online 2017 Apr 14 DOI: https://doi.org/10.3904/kjim.2015.299
|
|
Citations to this article as recorded by
 KRAS as a Prognostic and Predictive Marker in Metastatic Non-Small Cell Lung Carcinoma: A Systematic Review
Sheereen Fatima, Nirav Pansuriya, Alisha Lakhani, Sai Madhuri, Reshma Ajmal, Ruchira Clementina, Zahabiya Lakdawala, Kinjal Shah, Husna Dilshana, Maya Andrea, Bejoi Mathew, Aashna Raheja
Cureus.2024;[Epub] CrossRef MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta-Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, Laura Soucek
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef LncRNA-NEAT1 facilitates autophagy to boost pemetrexed resistance in lung adenocarcinoma via the mir-379-3p/HIF1A pathway
Wei Hu, Wenjun Cao, Jiheng Liu
Human & Experimental Toxicology.2024;[Epub] CrossRef WITHDRAWN: Oncogenic lncRNA MALAT-1 recruits E2F1 to upregulate RAD51 expression and thus promotes cell autophagy and tumor growth in non-small cell lung cancer
Rui Xin, Boqi Hu, Danhua Qu, Dawei Chen
Pulmonary Pharmacology & Therapeutics.2023; : 102199. CrossRef A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung Cancer
Peter Manolakos, Linda D. Ward
Journal of Personalized Medicine.2023; 13(6): 1010. CrossRef Therapeutic Outcomes and Clinical Features of Advanced Non–Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study
Giulia Mazzaschi, Fabiana Perrone, Roberta Minari, Michela Verzè, Cinzia Azzoni, Lorena Bottarelli, Monica Pluchino, Maria Pia Armillotta, Annalisa Ubaldi, Annalisa Altimari, Elisa Gruppioni, Francesca Sperandi, Elisa Andrini, Giorgia Guaitoli, Stefania B
Clinical Lung Cancer.2022; 23(7): e478. CrossRef Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer
Matthew Z. Guo, Joseph C. Murray, Paola Ghanem, K Ranh Voong, Russell K. Hales, David Ettinger, Vincent K. Lam, Christine L. Hann, Patrick M. Forde, Julie R. Brahmer, Benjamin P. Levy, Josephine L. Feliciano, Kristen A. Marrone
Clinical Lung Cancer.2022; 23(7): 620. CrossRef Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
Elona Cekani, Samantha Epistolio, Giulia Dazio, Marco Cefalì, Luciano Wannesson, Milo Frattini, Patrizia Froesch
Cancers.2022; 14(17): 4103. CrossRef Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer
Liyuan Gao, Weizhang Shen
Frontiers in Genetics.2022;[Epub] CrossRef Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma
Luwei Tao, Ruoyu Miao, Tarek Mekhail, Jingxin Sun, Lingbin Meng, Cheng Fang, Jian Guan, Akriti Jain, Yuan Du, Amanda Allen, Brenda L. Rzeszutko, Mark A. Socinski, Chung-Che Chang
Clinical Lung Cancer.2021; 22(4): e506. CrossRef KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
Martin Sebastian, Wilfried E.E. Eberhardt, Petra Hoffknecht, Martin Metzenmacher, Thomas Wehler, Konrad Kokowski, Jürgen Alt, Wolfgang Schütte, Reinhard Büttner, Lukas C. Heukamp, Albrecht Stenzinger, Martina Jänicke, Annette Fleitz, Stefan Zacharias, Ste
Lung Cancer.2021; 154: 51. CrossRef Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
Riccardo Giampieri, Alessio Lupi, Pina Ziranu, Alessandro Bittoni, Andrea Pretta, Federica Pecci, Mara Persano, Enrica Giglio, Cecilia Copparoni, Sonia Crocetti, Alessandra Mandolesi, Gavino Faa, Pierpaolo Coni, Mario Scartozzi, Rossana Berardi
Frontiers in Oncology.2021;[Epub] CrossRef Expression of PD-1/PD-L1 in lung adenocarcinoma and its clinical significance*
Jian Li, Yimin Chen
Oncology and Translational Medicine.2021; 7(1): 15. CrossRef Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer
B. Ricciuti, M. Brambilla, A. Cortellini, A. De Giglio, C. Ficorella, A. Sidoni, G. Bellezza, L. Crinò, V. Ludovini, S. Baglivo, G. Metro, R. Chiari
Clinical and Translational Oncology.2020; 22(5): 708. CrossRef A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations
Lei Lei, Wen-xian Wang, Zong-yang Yu, Xian-bin Liang, Wei-wei Pan, Hua-fei Chen, Li-ping Wang, Yong Fang, Min Wang, Chun-wei Xu, Mei-yu Fang
Translational Oncology.2020; 13(2): 329. CrossRef Notch Transduction in Non-Small Cell Lung Cancer
Amnah Sharif, Ann Shaji, May Chammaa, Eileen Pawlik, Rodrigo Fernandez-Valdivia
International Journal of Molecular Sciences.2020; 21(16): 5691. CrossRef New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Haitang Yang, Shun-Qing Liang, Ralph A. Schmid, Ren-Wang Peng
Frontiers in Oncology.2019;[Epub] CrossRef Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
Venus Sosa Iglesias, Lorena Giuranno, Ludwig J. Dubois, Jan Theys, Marc Vooijs
Frontiers in Oncology.2018;[Epub] CrossRef Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine
Jacqueline V. Aredo, Sukhmani K. Padda
Current Treatment Options in Oncology.2018;[Epub] CrossRef Realities of KRAS-mutated non-small cell lung cancer
Young Joo Min
The Korean Journal of Internal Medicine.2017; 32(3): 442. CrossRef
|